Abstract
Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.
Keywords: tumour necrosis factor aplha, Cytokines, TNF inhibitors, Psoriasis, Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Etanercept for the Treatment of Dermatological Diseases
Volume: 6 Issue: 3
Author(s): Goksun Karaman
Affiliation:
Keywords: tumour necrosis factor aplha, Cytokines, TNF inhibitors, Psoriasis, Inflammatory Diseases
Abstract: Inhibition of the proinflammatory cytokine TNF-α has been shown to be an effective strategy for treating inflammatory dermatoses. Etanercept competitively inhibits the interaction of TNF, interrupting the proinflammatory cytokine cascade and preventing TNF mediated cellular responses. The success of etanercept in a wide range of dermatologic conditions especially in psoriasis gives a new hope in dermatological therapy field. This article reviews the pharmacokinetic properties, safety profile, administration route and efficacy in different dermatological conditions of etanercept.
Export Options
About this article
Cite this article as:
Goksun Karaman , Etanercept for the Treatment of Dermatological Diseases, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2007; 6 (3) . https://dx.doi.org/10.2174/187152307781368256
DOI https://dx.doi.org/10.2174/187152307781368256 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characteristics of Peripheral Blood Stem Cells: 2D-Gel Electrophoresis and Kinetic Parameter of Exocytosis
Current Biomarkers (Discontinued) Oxazol-5-(4H)-Ones. Part 1. Synthesis and Reactivity as 1,3-dipoles
Current Organic Chemistry Therapeutic Drug Monitoring of Busulfan in Transplantation
Current Pharmaceutical Design Mikuliczs Disease and its Extraglandular Lesions
Current Immunology Reviews (Discontinued) MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Antiphospholipid Antibody-Mediated Thrombotic Mechanisms in Antiphospholipid Syndrome: Towards Pathophysiology-Based Treatment
Current Pharmaceutical Design Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia
Current Drug Safety A Very Rare Cerebral Complication of Chemotherapy in a Young Girl: A Difficult Diagnosis
Current Drug Safety Advances in Immunotherapy of Chronic Myeloid Leukemia CML
Current Cancer Drug Targets Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Antitumoral Activity of Interferon-γ Involved in Impaired Immune Function in Cancer Patients
Current Drug Metabolism Recent Advances in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology Editorial
Current Pharmaceutical Biotechnology Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Review of Recent Clinical Developments and Patents for the Treatment of Autoimmune and Inflammatory Diseases by Mesenchymal Stromal Cells
Recent Patents on Regenerative Medicine Cellular Changes, Molecular Pathways and the Immune System Following Photodynamic Treatment
Current Medicinal Chemistry Glioma Therapy: A Novel Insight in the Immunotherapeutic Regime with T11TS/SLFA-3
Central Nervous System Agents in Medicinal Chemistry Regulation of Dendritic Cell Function with Immunomodulatory Drugs
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials Proteomic Strategies for Individualizing Therapy of Acute MyeloidLeukemia (AML)
Current Pharmaceutical Biotechnology